Efficacy and safety of cluster immunotherapy for 154 patients with allergic rhinitis.
- Author:
Luo ZHANG
1
;
Cheng-Shuo WANG
;
Xiang-Dong WANG
;
Yan ZHAO
;
Jian-Hui LIU
;
Wei ZHANG
;
Bing ZHOU
;
De-Min HAN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Allergens; Animals; Antigens, Dermatophagoides; immunology; Child; Dermatophagoides farinae; immunology; Female; Humans; Immunotherapy; adverse effects; Male; Middle Aged; Rhinitis; parasitology; therapy; Treatment Outcome; Young Adult
- From: Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2008;43(3):187-191
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of cluster immunotherapy with Dermatophagoides pteronyssinus for allergic rhinitis.
METHODSOne hundred and fifty-four patients with allergic rhinitis to Dermatophagoides pteronyssinus were allocated to receive specific immunotherapy in a 6-week cluster schedule during the incremental-dose phase. Thereafter, these patients received maintenance-dose injection at 6-week intervals until the end of 1 year of treatment. Symptom scores and medication scores were used to evaluate the clinical efficacy and adverse reactions were recorded. A rhinoconjunctivitis quality of life questionnaire (RQLQ) was completed in the baseline and after one year treatment.
RESULTSCluster immunotherapy significantly reduced the symptom scores and total medication score of patients enrolled (P < 0.01). The immunotherapy group also had a significant improvement in the Rhinoconjunctivitis Quality of Life Questionnaire. During the one-year of treatment, there were 26 systemic adverse reactions (0.75% of all injection) in 9 patients (5.9%) and no fatal systemic reactions occurred.
CONCLUSIONSThe cluster immunotherapy is efficacious and safe to treat allergic rhinitis.
